Better known by Novo Nordisk's brand names Ozempic and Wegovy (the former of which is indicated only for type 2 diabetes), ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results ...

The position in Novo Nordisk hindered returns as the company’s Wegovy obesity treatment missed revenue expectations due to a ...

The agency is also evaluating Novo Nordisk’s (NVO) semaglutide drugs for the same label. After significant pushback, the FDA ...

Without giving specific details, Amgen said it was encouraged by the data and was confident in MariTide's "differentiated ...

Also worth noting, the trial did not involve titration—a dose increase period currently required for Eli Lilly’s Zepbound and ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

If you said diabetes, you're right -- a new study finds diabetes costs $101 billion annually in diagnosis and treatment and ...

While semaglutide remains on the shortage list, Novo Nordisk noted last week that the last remaining dose in short supply — the lowest dose of Wegovy — is now listed as available, CNN reported. “We’re ...